C-MYC aberrations as prognostic factors in diffuse large b-cell lymphoma: A meta-analysis of epidemiological studies

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Zhou, Kuangguo ^a   Xu, Danmei ^a   Cao, Yang ^a   Wang, Jue ^a   Yang, Yunfan ^a   Huang, Mei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; IFOSFAMIDE; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BONE MARROW; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; EVENT FREE SURVIVAL; GENE AMPLIFICATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENETIC DISORDER; GENETIC SCREENING; HUMAN; LARGE CELL LYMPHOMA; ONCOGENE C MYC; OVERALL SURVIVAL; PRACTICE GUIDELINE; SYSTEMATIC REVIEW; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; GENE REARRANGEMENT; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; META ANALYSIS; MULTIVARIATE ANALYSIS; ONCOGENE MYC; OUTCOME ASSESSMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; EPIDEMIOLOGIC STUDIES; GENE AMPLIFICATION; GENE REARRANGEMENT; GENES, MYC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84899726538     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095020     Document Type: Article

References (45)

1. Sehn LH (2012) Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2012: 402-409.
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987-994.
3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242. (Pubitemid 34438862)
4. Perry AM, Mitrovic Z, Chan WC (2012) Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control 19: 214-226.
5. Slack GW, Gascoyne RD (2011) MYC and aggressive B-cell lymphomas. Adv Anat Pathol 18: 219-228.
6. Pfreundschuh M (2012) Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas. J Clin Oncol 30: 3433-3435.
7. Akyurek N, Uner A, Benekli M, Barista I (2012) Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 118: 4173-4183.
8. Barrans S, Crouch S, Smith A, Turner K, Owen R, et al. (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28: 3360-3365.
9. Cuccuini W, Briere J, Mounier N, Voelker HU, Rosenwald A, et al. (2012) MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or RDHAP followed by BEAM plus autologous stem cell transplantation. Blood 119: 4619-4624.
10. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, et al. (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, Doxorubicin, vincristine, and prednisone. J Clin Oncol 30: 3460-3467.
11. Gupta M, Maurer MJ, Wellik LE, Law ME, Han JJ, et al. (2012) Expression of Myc but not pSTAT3, is an adverse prognostic factor for diffuse large cell lymphoma treated with epratuzumab/R-CHOP. Blood 119:4400-4406.
12. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, et al. (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354: 2419-2430. (Pubitemid 43855045)
13. Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, et al. (2008) Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 22: 2226-2229.
14. Kluk MJ, Chapuy B, Sinha P, Roy A, Dal-Cin P, et al. (2012) Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 7: e33813.
15. Kojima M, Nishikii H, Takizawa J, Aoki S, Noguchi M, et al. (2013) MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma. Leuk Lymphoma 54: 2149-2154.
16. McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, et al. (2005) Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol 29: 1652-1660.
17. Nitsu N, Okamoto M, Miura I, Hirano M (2009) Clinical significance of 8q24/c- MYC translocation in diffuse large B-cell lymphoma. Cancer Sci 100: 233-237.
18. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, et al. (2008) Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 112: 3425-3433.
19. Saez AI, Artiga MJ, Romero C, Rodriguez S, Cigudosa JC, et al. (2003) Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc+ diffuse large B-cell lymphoma. Lab Invest 83: 143-152. (Pubitemid 36255360)
20. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, et al. (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114: 3533-3537.
21. Zhang HW, Chen ZW, Li SH, Bai W, Cheng NL, et al. (2011) Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma. Hematol Oncol 29: 185-189.
22. Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, et al. (2013) Biologic characterization of adult MYC-translocation positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica Epub ahead of print.
23. Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, et al. (2013) Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol [Epub ahead of print].
24. Perry AM, Alvarado-Bernal Y, Laurini JA, Smith LM, Slack GW, et al. (2014) MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol [Epub ahead of print].
25. Akasaka T, Akasaka H, Ueda C, Yonetani N, Maesako Y, et al. (2000) Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin Oncol 18: 510-518. (Pubitemid 30078532)
26. Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, et al. (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large Bcell lymphoma. Blood 121:2253-2263.
27. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, et al. (2012) Concurrent expression of MYC and BCL2 in diffuse large B-Cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30: 3452-3459.
28. Kawasaki C, Ohshim K, Suzumiya J, Kanda M, Tsuchiya T, et al. (2001) Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas. Leuk Lymphoma 42: 1099-1106. (Pubitemid 32827531)
29. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, et al. (1998) Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92: 3152-3162. (Pubitemid 28492322)
30. Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, et al. (2008) MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology 53: 205-217. (Pubitemid 352032771)
31. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6: e1000097.
32. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25: 603-605.
33. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23: 9067-9072.
34. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. (Pubitemid 28562978)
35. Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, et al. (2012) Prognostic value of survivin in patients with non-small cell lung carcinoma: A systematic review with meta-analysis. PLoS One 7: e34100.
36. Moja L, Piatti A, Pecoraro V, Ricci C, Virgili G, et al. (2012) Timing matters in hip fracture surgery: patients operated within 48 hours have better outcomes. A meta-analysis and meta-regression of over 190, 000 patients. PLoS One 7: e46175.
37. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
38. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
39. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, et al. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immuno histochemistry using a tissue microarray. Blood 103: 275-282. (Pubitemid 38029949)
40. Testoni M, Kwee I, Greiner TC, Montes-Moreno S, Vose J, et al. (2011) Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Br J Haematol 155: 274-277.
41. Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, et al. (2013) Patients with diffuse large B cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: A report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 98:255-263.
42. Mossafa H, Damotte D, Jenabian A, Delarue R, Vincenneau A, et al. (2006) Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk Lymphoma 47: 1885-1893. (Pubitemid 44649774)
43. Stasik CJ, Nitta H, Zhang W, Mosher CH, Cook JR, et al. (2010) Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica 95: 597-603.
44. Valentino C, Kendrick S, Johnson N, Gascoyne R, Chan WC, et al. (2013) Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma. Am J Clin Pathol 139: 242-254.
45. Green TM, Nielsen O, de Stricker K, Xu-Monette ZY, Young KH, et al. (2012) High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol 36: 612-619.